[1]张毅 罗勤 赵智慧 赵青 柳志红.心肺运动试验应用于系统性硬化病相关肺动脉高压筛查的研究进展[J].心血管病学进展,2021,(7):577-581,589.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.001]
　ZHANG Yi,LUO Qin,ZHAO Zhihui,et al.Cardiopulmonary Exercise Test for Screening of Systemic Sclerosis-Associated Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(7):577-581,589.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.001]
点击复制

心肺运动试验应用于系统性硬化病相关肺动脉高压筛查的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年7期
页码:
577-581,589
栏目:
出版日期:
2021-07-25

文章信息/Info

Title:
Cardiopulmonary Exercise Test for Screening of Systemic Sclerosis-Associated Pulmonary Hypertension
作者:
张毅 罗勤 赵智慧 赵青 柳志红
(中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院,北京100037)
Author(s):
ZHANG Yi;  LUO Qin;  ZHAO Zhihui;  ZHAO Qing;  LIU Zhihong
(Fuwai Hospital,National Center for Cardiovascular Disease,Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, China) (Z181100001718200)(7202168) E-mailzhihongliufuwai@163.com
关键词:
心肺运动试验; 系统性硬化病; 肺动脉高压; 筛查
Keywords:
Cardiopulmonary exercise test;  Systemic sclerosis;  Pulmonary hypertension;  Screening
DOI:
10.16806/j.cnki.issn.1004-3934.2021.07.001
摘要:
肺动脉高压是结缔组织病的严重并发症之一，其中以系统性硬化病相关肺动脉高压和系统性红斑狼疮相关肺动脉高压最为常见。因早期症状不明显，大多数系统性硬化病相关肺动脉高压直至出现严重的临床症状，以及功能状态严重受损时才被确诊。虽然目前有一些有效的筛查手段，但它们在适用人群、特异度和阴性预测值等方面尚不能令人满意。心肺运动试验是评估患者运动耐量的金标准。通过比较合并与不合并肺动脉高压的系统性硬化病患者，在运动负荷状态下心肺功能的差异，或许能为系统性硬化病相关肺动脉高压的筛查开拓出新的道路。现就近年来心肺运动试验应用于系统性硬化病相关肺动脉高压筛查的研究进展做一综述。
Abstract:
Pulmonary hypertension is one of the serious complications of connective tissue. Systemic sclerosis -associated pulmonary hypertension and systemic lupus erythematosus-associated pulmonary hypertension are the most common. Most individuals present with severe symptoms and significant functional impairment at diagnosis, because they tend to be asymptomatic at early stage. Although there are some effective screening methods, they are not satisfactory in terms of applicable population, specificity and negative predictive value. Cardiopulmonary exercise test is the gold standard for the assessment of exercise capacity. By comparing the difference of cardiopulmonary function between patients with and without pulmonary hypertension under exercise load, it may open up a new way for the screening of systemic sclerosis-associated pulmonary hypertension. This article reviews the research progress of cardiopulmonary exercise test in screening systemic sclerosis-associated pulmonary hypertension in recent years

参考文献/References:

[1].Babu AS,Morris NR,Arena R,et al. Exercise-based evaluations and interventions for pulmonary hypertension with connective tissue disorders[J]. Expert Rev Respir Med,2018,12(7):615-622.
[2].[2] Avouac J,Airo P,Meune C,et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies[J]. J Rheumatol,2010,37(11):2290-2298.
[3].[3] Mukerjee D,St George D,Coleiro B,et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension:application of a registry approach[J]. Ann Rheum Dis,2003,62(11):1088-1093.
[4].[4] Hachulla E,Gressin V,Guillevin L,et al. Early detection of pulmonary arterial hypertension in systemic sclerosis:a French nationwide prospective multicenter study[J]. Arthritis Rheum,2005,52(12):3792-3800.
[5].[5] Steen VD,Medsger TA. Changes in causes of death in systemic sclerosis,1972-2002[J]. Ann Rheum Dis,2007,66(7):940-944.
[6].[6] Launay D,Sitbon O,Hachulla E,et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era[J]. Ann Rheum Dis,2013,72(12):1940-1946.
[7].[7] Valerio CJ,Schreiber BE,Handler CE,et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis:transpulmonary gradient predicts risk of developing pulmonary hypertension[J]. Arthritis Rheum,2013,65(4):1074-1084.
[8].[8] Coghlan JG,Wolf M,Distler O,et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis[J]. Eur Respir J,2018,51(4):1701197.
[9].[9] Humbert M,Yaici A,de Groote P,et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis:clinical characteristics at diagnosis and long-term survival[J]. Arthritis Rheum,2011,63(11):3522-3530.
[10].[10] Gaine S,Chin K,Coghlan G,et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension[J]. Eur Respir J,2017,50(2):1602493.
[11].[11] Coghlan JG,Galie N,Barbera JA,et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension(CTD-PAH):subgroup analysis from the AMBITION trial[J]. Ann Rheum Dis,2017,76(7):1219-1227.
[12].[12] Lau EM,Humbert M,Celermajer DS. Early detection of pulmonary arterial hypertension[J]. Nat Rev Cardiol,2015,12(3):143-155.
[13].[13] Young A,Nagaraja V,Basilious M,et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension[J]. Semin Arthritis Rheum,2019,48(6):1059-1067.
[14].[14] Bruni C,de Luca G,Lazzaroni MG,et al. Screening for pulmonary arterial hypertension in systemic sclerosis:a systematic literature review[J]. Eur J Intern Med,2020,78:17-25.
[15].[15] Coghlan JG,Denton CP,Grunig E,et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:the DETECT study[J]. Ann Rheum Dis,2014,73(7):1340-1349.
[16].[16] Pinkstaff SO,Burger CD,Daugherty J,et al. Cardiopulmonary exercise testing in patients with pulmonary hypertension:clinical recommendations based on a review of the evidence[J]. Expert Rev Respir Med,2016,10(3):279-295.
[17].[17] 赵青,马秀平,罗勤,等. 应用心肺运动试验评价动脉性肺动脉高压靶向药物疗效[J]. 中国循环杂志,2020,35(8):750-754.
[18].[18] 唐毅,罗勤,柳志红,等. 摄氧效率斜率预测特发性肺动脉高压预后[J]. 中国循环杂志,2017,32(4):367-371.
[19].[19] Guazzi M,Adams V,Conraads V,et al. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations[J]. Eur Heart J,2012,33(23):2917-2927.
[20].[20] Farina S,Correale M,Bruno N,et al. The role of cardiopulmonary exercise tests in pulmonary arterial hypertension[J]. Eur Respir Rev,2018,27(148):170134.
[21].[21] Boutou AK,Pitsiou GG,Siakka P,et al. Phenotyping exercise limitation in systemic sclerosis: the use of cardiopulmonary exercise testing[J]. Respiration,2016,91(2):115-123.
[22].[22] Sun XG,Hansen JE,Oudiz RJ,et al. Exercise pathophysiology in patients with primary pulmonary hypertension[J]. Circulation,2001,104(4):429-435.
[23].[23] Ferrazza AM,Martolini D,Valli G,et al. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases[J]. Respiration,2009,77(1):3-17.
[24].[24] Correale M,Tricarico L,Ferraretti A,et al. Cardiopulmonary exercise test predicts right heart catheterization[J]. Eur J Clin Invest,2017,47(12). DOI: 10.1111/eci.12851. Epub 2017 Nov 17.
[25].[25] Tsuboi Y,Tanaka H,Nishio R,et al. Associations of exercise tolerance with hemodynamic parameters for pulmonary arterial hypertension and for chronic thromboembolic pulmonary hypertension[J]. J Cardiopulm Rehabil Prev,2017,37(5):341-346.
[26].[26] Pudasaini B,Yang GL,Yang C,et al. Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients[J]. BMC Cardiovasc Disord,2018,18(1):56.
[27].[27] Montani D,Girerd B,Ja?s X,et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation[J]. Eur Respir J,2020,30:2004229.
[28].[28] Held M,Grun M,Holl R,et al. Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography[J]. Respiration,2014,87(5):379-387.
[29].[29] Zhao QH,Wang L,Pudasaini B,et al. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension[J]. Clin Cardiol,2017,40(2):95-101.
[30].[30] Dumitrescu D,Oudiz RJ,Karpouzas G,et al. Developing pulmonary vasculopathy in systemic sclerosis,detected with non-invasive cardiopulmonary exercise testing[J]. PLoS One,2010,5(12):e14293.
[31].[31] Bernstein EJ,Mandl LA,Gordon JK,et al. Submaximal heart and pulmonary evaluation:a novel noninvasive test to identify pulmonary hypertension in patients with systemic sclerosis[J]. Arthritis Care Res(Hoboken),2013,65(10):1713-1718.
[32].[32] Bernstein EJ,Gordon JK,Spiera RF,et al. Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension[J]. Rheumatology(Oxford),2017,56(1):87-94.
[33].[33] Dumitrescu D,Nagel C,Kovacs G,et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis[J]. Heart,2017,103(10):774-782.
[34].[34] Galie N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS):endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC),International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J,2016,37(1):67-119.
[35].[35] Reichenberger F,Voswinckel R,Schulz R,et al. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma[J]. Respir Med,2009,103(11):1713-1718. [36] Bossone E,Rubenfire M,Bach DS,et al. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men:implications for the diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol,1999,33(6):1662-1666.
[36].[37] Santaniello A,Casella R,Vicenzi M,et al. Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis[J]. Rheumatology(Oxford),2019,59(7):1581-1586.
[37].[38] Tan X,Yang W,Guo J,et al. Usefulness of decrease in oxygen uptake efficiency to identify gas exchange abnormality in patients with idiopathic pulmonary arterial hypertension[J]. PLoS One,2014,9(6):e98889.
[38].[39] Sun XG,Hansen JE,Stringer WW. Oxygen uptake efficiency plateau:physiology and reference values[J]. Eur J Appl Physiol,2012,112(3):919-928.
[39].[40] Thakkar V,Stevens WM,Prior D,et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis:a case-control study[J]. Arthritis Res Ther,2012,14(3):R143.
[40].[41] Hachulla E,Gressin V,Guillevin L,et al. Pulmonary arterial hypertension in systemic sclerosis:definition of a screening algorithm for early detection(the ItinerAIR-Sclerodermie Study)[J]. Rev Med Interne,2004,25(5):340-347.
[41].[42] Chung L,Liu J,Parsons L,et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL:identifying systemic sclerosis as a unique phenotype[J]. Chest,2010,138(6):1383-1394.
[42].[43] Condliffe R,Kiely DG,Peacock AJ,et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era[J]. Am J Respir Crit Care Med,2009,179(2):151-157.
[43].[44] Hao YJ,Jiang X,Zhou W,et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J]. Eur Respir J,2014,44(4):963-972.
[44].[45] Kang KY,Jeon CH,Choi SJ,et al. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography:results from a Korean nationwide registry[J]. Int J Rheum Dis,2017,20(9):1227-1236.
[45].[46] Shirai Y,Yasuoka H,Okano Y,et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension:a single-centre cohort[J]. Rheumatology(Oxford),2012,51(10):1846-1854.
[46].[47] Bazan IS,Mensah KA,Rudkovskaia AA,et al. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus:a review[J]. Respir Med,2018,134:42-46.
[47].[48] Huang D,Cheng YY,Chan PH,et al. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus(SOPHIE) study[J]. ERJ Open Res,2018,4(1):00135-2017.
[48].[49] 熊长明,翟振国,王辰. 修改肺动脉高压诊断标准带来的争议及其影响[J]. 中华医学杂志,2020,100(22):1684-1687.

相似文献/References:

[1]蒋昭隆,刘剑雄.心肺运动试验在心脏瓣膜病的运用现状[J].心血管病学进展,2019,(6):951.[doi:10.16806/j.cnki.issn.1004-3934.201.06.028]
　JIANG Zhaolong,LIU Jianxiong.Application of Cardiopulmonary Exercise Test in Cardiac Valvular Disease[J].Advances in Cardiovascular Diseases,2019,(7):951.[doi:10.16806/j.cnki.issn.1004-3934.201.06.028]
[2]蒋昭隆刘剑雄.心肺运动试验在冠心病运用现状[J].心血管病学进展,2019,(9):1290.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.027]
　JIANG Zhaolong,LIU Jianxiong.Current Status of Cardiopulmonary Exercise Test in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):1290.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.027]
[3]谢佳 唐红 徐婷 边叶婷.心肺运动试验在右心疾病中的应用[J].心血管病学进展,2021,(10):873.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.003]
　XIE JiaTANG HongXU TingBIAN Yeting.Application of Cardiopulmonary Exercise Test in Right Heart Disease[J].Advances in Cardiovascular Diseases,2021,(7):873.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.003]
[4]宋燕新 刘萍 赵威.分钟通气量和二氧化碳生成量关系对于心力衰竭患者的价值[J].心血管病学进展,2022,(5):419.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.009]
　SONG Yanxin,LIU Ping,ZHAO Wei.Value of the Relationship of VE and VCO2 in Heart Failure Patients[J].Advances in Cardiovascular Diseases,2022,(7):419.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.009]
[5]应桃 吴镜.心肺运动试验在呼吸系统疾病中的应用[J].心血管病学进展,2023,(4):365.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.017]
　YING Tao,WU Jing.Application of Cardiopulmonary exercise testing in respiratory disease[J].Advances in Cardiovascular Diseases,2023,(7):365.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.017]
[6]蔡珍 徐英 刘思捷 艾婷婷.心肺运动试验与冠心病相关性的研究进展[J].心血管病学进展,2024,(6):502.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.006]
　CAI Zhen,XU Ying,LIU Sijie,et al.Cardiopulmonary Exercise Test and Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2024,(7):502.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.006]
[7]何璐 吴镜.心肺运动试验对肺动脉高压的临床意义[J].心血管病学进展,2024,(6):506.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.007]
　HE Lu,WU Jing.Clinical Significance of Cardiopulmonary Exercise Test for Pulmonary Hypertention[J].Advances in Cardiovascular Diseases,2024,(7):506.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.007]

更新日期/Last Update: 2021-09-10